Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Allan Klein, MD


Allan Klein, MD
Department: Cardiovascular Medicine
Location: Cleveland Clinic Main Campus
Mail Code J1-5
9500 Euclid Avenue
Cleveland, OH 44195
Type of Doctor:
Adults Only

Biographical Sketch

Allan Klein, MD, is the Director of Cardiovascular Imaging Research, Director of the Center for the Diagnosis and Treatment of Pericardial Diseases, and a staff cardiologist in the Section of Cardiovascular Imaging, the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, at the Sydell and Arnold Miller Family Heart & Vascular Institute.  He is also the Course Director for Diastology and Contrast Echo & New Technologies Courses—currently his 15th annual course.  He is board-certified in internal medicine and cardiovascular medicine.  His specialty interests include cardiovascular imaging (echocardiography, cardiac MR and computed tomography); pericardial diseases; restrictive cardiomyopathies; valvular heart disease; atrial fibrillation; and diastolic heart failure.

A Canadian by birth, Dr. Klein speaks fluent French and English.  He received his medical degree from McGill University in Montreal, Quebec after completing an undergraduate degree in microbiology and immunology, graduating with honors.  While in medical school, he received several scholarships and graduated in the top 10 percent of his class.  Dr. Klein completed his clinical training at Mount Sinai Hospital in Toronto and the Royal Victoria Hospital in Montreal.  He completed a Cardiology Residency from the University of Ottawa Heart Institute and a Research Fellowship from the Mayo Clinic in Rochester, Minn.  He was appointed to Cleveland Clinic in 1989.

In addition to his scholarships and academic achievements, Dr. Klein won the E.G.D. Murray Prize in Microbiology and Immunology as an undergraduate and has received multiple American Society of Echocardiography Outcomes Research Awards.

Dr. Klein has been course director and workshop leader at numerous medical specialty conferences focused on clinical trials, imaging modalities and clinical protocols, to name a few.  He currently serves as Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western University.  Dr. Klein is a member of the Lerner College of Medicine Admissions Committee.

He is also principal or co-principal investigator for multicenter clinical trials in atrial fibrillation (ACUTE I, ACUTE II, and CLOTS); studies in diastolic function (ADEPT); valvular heart disease (Anorexigens and Valve Disease); and catheter ablation and pulmonary vein flow (ROTEA).  Dr. Klein was honored to present the first online video summary of the ROTEA study for the Journal of the American Society of Echocardiography.  He has published key articles in such prestigious journals such as New England Journal of Medicine, Lancet, European Heart Journal, Circulation, and the Journal of the American College of Cardiology.

Dr. Klein has served on the Board of Directors of the American Society of Echocardiography and is now Chair of the Industry Relations Committee.  He is also on the Writing Committee for the National Board of Echocardiography.  Dr. Klein serves as a peer reviewer for more than 15 professional journals.  He also grades abstracts for the American College of Cardiology, the American Society of Echocardiography, the American Heart Association, and the European Society of Cardiology.

He has been an invited lecturer at many national and international symposia and conferences, speaking on topics related to his specialty interests.  Dr. Klein has authored or co-authored more than 210 peer-reviewed articles in professional journals, written 26 chapters in medical textbooks and published more than 360 abstracts.  He is a co-editor of two books entitled "Diastology: Clinical Approach to Diastolic Heart Failure." as well as "Clinical Echocardiography Review: A Self-Assessment Tool."

Dr. Klein is a Fellow in the Council on Clinical Cardiology, the American College of Cardiology, and the Royal College of Physicians (Canada).  In addition, he is a member of the American Society of Echocardiography, the American Medical Association and the American Heart Association.

Professional Highlights

  • 2007:  Grand Rounds presentation at Massachusetts General Hospital on "New Advances in Echocardiography in Atrial Fibrillation:  What's New in the LAA and Pulmonary Veins?"
  • 2006:  Publication of “The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transesophageal echocardiography-guided cardioversion:  Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II randomized multicentre study” in the European Heart Journal
  • 2006:  Key note speaker on "New Advances in Echocardiography in Atrial Fibrillation" in Rome at the X World Congress of Echocardiography & Cardiovascular Imaging Conference
  • 2004:  Publication of “Pericarditis” in The Lancet
  • 2001:  Publication of “Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation” in the New England Journal of Medicine

Education & Fellowships

Fellowship - Mayo Clinic
Cardiovascular Diseases
Rochester, MN USA
Residency - University of Ottawa Heart Institute
Ottawa, Ontario Canada
Residency - Royal Victoria Hospital
Internal Medicine
Montreal, Quebec Canada
Internship - Mount Sinai Hospital
Internal Medicine
Toronto, Ontario Canada
Medical School - McGill University Faculty of Medicine
Montreal, Quebec Canada
Undergraduate - McGill University
Montreal, Quebec Canada


  • Internal Medicine
  • Internal Medicine- Cardiovascular Disease

Specialty Interests

Amyloidosis, Heart Valve Disease, Pericardial Disease, Pericarditis, Cardiovascular imaging, Echocardiogram, Non-invasive Diagnostic Testing

Awards & Honors

  • Fellowships: American College of Cardiology, Royal College of Physicians (Canada), American Society of Echocardiography, American Heart Association
  • Principal Investigator for harmonic imaging of the left atrial appendage with atrial  fibrillation study (CLOTS)
  • Principal Investigator for the ACUTE II Low Molecular Weight Heparin study
  • Principal Investigator for A Pilot Phase 3, International, Multicenter, Open-label, Dual Injection,
  • Myocardial Imaging and Safety Study of AI-700 in patients with Suspected Ischemic Heart Disease
  • Principal Investigator for the American Society of Echo. Research Award for “Predication of Responses to Beta-Blocker Therapy in Heart Failure Using Doppler Filling Patterns of the Left Ventricle”
  • Principal Investigator for the American Society of Echo. Outcomes Award. The Role of Transesophageal Echocardiography in Pulmonary Vein Ablation: Comparison with Computed Tomography: The ROTEA Study
  • Principal Investigator.  Low Molecular Weight Heparin in Bridging Patients after Mechanical Valve Replacement. (ABRIDGE MVR Study)

Additional Training

  • Participant in the Cleveland Clinic's Cardiovascular CT Training Program in March, 2006 (Level II certification)
  • Participant at the 5th Annual Cardiovascular Magnetic Resonance & Computed Tomography Conference, June,2007. Effective January 2, 2008, met the Level 2 requirements for training in Cardiac CT (CCT) based on the ACCF/AHA Clinical Competency Statement on Cardiac Imaging with Computed Tomography and Magnetic Resonance

Innovations & Patents

Dr. Klein has pioneered the use of transesophageal-guided cardioversion in patients with atrial fibrillation in his landmark paper in the New England Journal of Medicine published in 2001 and the European Heart Journal in 2006. 

He is also the Director of the echocardiographic symposiums entitled Diastology and New Echo Technologies and is the editor of a book entitled "Diastology:  Clinical Approach to Diastolic Heart Failure."


  • American Society of Echocardiography
  • American Heart Association
  • American College of Cardiology
  • Royal College of Physicians
  • Society of Cardiovascular Computed Tomography

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 5/1/2016, Dr. Klein has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
  • French

Patient Satisfaction Reviews

Learn About Our Survey


The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.